Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 12/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 12/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8679135 | 0.90 | L3MBTL1 (0.36) | ALDH1A1 | |
| SCHEMBL8485778 | 0.88 | NPY1R (0.37) | RORCAOC3NPY1RNPY5RSCN1A | |
| SCHEMBL8666046 | 0.87 | L3MBTL1 (0.34) | ALDH1A1 | |
| SCHEMBL8504367 | 0.84 | KCNA5 (0.32) | ALDH1A1 | |
| SCHEMBL8664324 | 0.83 | NPY1R (0.35) | RORCAOC3NPY1RNPY5RSCN1A | |
| SCHEMBL8480060 | 0.82 | CCR3 (0.40) | NPSR1 | |
| SCHEMBL8487926 | 0.82 | NPY1R (0.36) | RORCAOC3NPY1RNPY5RSCN1A | |
| SCHEMBL8479608 | 0.81 | NPY1R (0.36) | RORCAOC3NPY1RNPY5RSCN1A | |
| SCHEMBL8502233 | 0.80 | GAA (0.34) | RORCNPY1RNPY5RSCN1ASCN5A | |
| SCHEMBL8665214 | 0.80 | MCHR1 (0.37) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5883099-A | TREATMENT OF ATHERSCLEROSIS, PANCREATITIS OBESITY OR HYPERGLYCEMIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| US-H1729-H | Method for preparing compounds employing solid phase synthesis and novel linker-resin | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739135-A | PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-14 | — | — | US | disclosed |